Provider: Directors Deals Ltd.
Innate Pharma SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Innate Pharma SA Announces Results of Phase 1 Trial in AML
Innate Pharma SA announced that the results of the Phase I trial of IPH2101 (hybridoma anti-KIR antibody) in elderly patients with Acute Myeloid Leukemia in first complete remission were published online in the journal Blood. The Phase I trial evaluated the safety, tolerability and pharmacological profile of IPH2101 in elderly AML patients in complete remission after induction and consolidation treatment. The trial featured a dose-escalation protocol with seven dose levels (from 0.0003 to 3 mg/kg with 3 patients per dose level) and a single dose administration. The objective was to determine a safe and pharmacologically active dose. Twenty three patients were enrolled in this study. Tolerance was observed at all tested doses of IPH2101, adverse events were mild and transient. The maximum tolerated dose was not reached. A clear relationship between dose, blood concentration and receptor occupancy was observed, in accordance with preclinical models and with low inter-patient variability. Neither hematologic toxicity nor changes in numbers and distribution of lymphocyte subsets, NK cell receptor expression, or in vitro cytotoxicity were seen. At the highest dose levels, transient increase in TNF-α and MIP-1β serum concentrations and NK cell CD69 expression were observed.
Latest Developments for Innate Pharma SA
Latest Key Developments in Biotechnology
- Synta Pharmaceuticals Corp announces positive interim results from the ENCHANT-1 Trial
- Celator Pharmaceuticals Inc announces positive data and safety monitoring board recommendation for CPX-351 Phase 3 Study
- Kindred Biosciences Inc announces pricing of IPO
- Novation Holdings Inc announces auditor change - Form 8-K
- Share this
- Digg this